UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

  AMENDMENT NO. 1 TO

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 31, 2019

 

CANCER GENETICS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-35817   04-3462475
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

201 Route 17 North 2nd Floor, Rutherford, New Jersey   07070
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code (201) 528-9200

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

[  ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
[  ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
[  ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
[  ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined by Rule 405 of the Securities Act of 1933 (17 §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   CGIX   The Nasdaq Capital Market

 

 

 

 

 

 

EXPLANATORY NOTE

 

On June 3, 2019, Cancer Genetics, Inc. (the “Company”) filed a Current Report on Form 8-K (the “Original Report”) to, among other things, report on the voting results of its annual meeting of stockholders held on May 31, 2019 (the “Annual Meeting”), including, among other matters, the results of the advisory vote of the stockholders on the frequency of future advisory votes on executive compensation. This Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) is being filed to disclose the Company’s decision as to how frequently it will hold an advisory vote on executive compensation. Except as set forth in this Amendment, the disclosure contained in the Original Report remains unchanged.

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

As reported in the Original Report, the stockholders of the Company approved by a plurality of the votes cast at the Annual Meeting a proposal to hold an advisory vote on executive compensation every year. In light of this result and after further discussion by the Board of Directors of the Company (the “Board”), the Board determined at its meeting on July 18, 2019, that, until the next required advisory vote on the frequency of future advisory votes on executive compensation, the Company will hold an advisory vote on executive compensation every year.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CANCER GENETICS, INC.
     
  By: /s/ John A. Roberts
  Name:  John A. Roberts
  Title: Chief Executive Officer
     
Date: July 25, 2019    

 

 

 

 

 

Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Cancer Genetics Charts.
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Cancer Genetics Charts.